The lack of innovation ability of domestic drugs is related to the lack of participation of clinicians

Source: on June 1, 2016, the people's daily accelerated the progress of new drug research and development in China, which needs the support from the system and policy level, and also needs the source power of innovation It is not good to keep up with the trend Recently, the national health and Family Planning Commission announced the results of the first batch of drug price negotiations The prices of three kinds of best-selling life-saving drugs were cut back by more than 50%, known as "hard won progress of national drug price negotiations" Behind the success of the negotiation, we can't do without the presence of the government, but the negotiation is not based on administrative instructions We need to use our strength to speak Our chips are "exchange quantity for price" and "exchange medical insurance for drug price" In terms of drug prices, multinational drug companies rarely compromise, basically do nothing, and will not easily "cut flesh" Guangdong Province once concentrated on bidding for a 22000 yuan imported anti breast cancer drug, which was only reduced by 0.21 yuan, and the price reduction was only 1 / 100000 Imported medicine is so good because it is irreplaceable The emperor's daughter does not worry about marriage We still lack the strength to bargain with it Winning the negotiation also depends on the growth of domestic innovative drugs In this paper, we take exetane hydrochloride as an example, which is regarded as "domestic Iressa" It took 8 years to develop and was completely original by our country As the third lung cancer targeted anticancer drug in the world and the first one in Asia, it broke the monopoly situation of imported targeted drugs, and made more lung cancer patients use targeted anticancer drugs at a price lower than 30% - 40% of imported drugs "No innovation, no innovation is slow" To form mass innovation and speed up the progress of new drug research and development in China, we need support from the system and policy level, but also need the source power of innovation Follow the trend innovation is called "me too" mode in the industry Public information shows that in the first half of 2014, the largest proportion of anti-tumor drugs in chemical 1.1 new drug varieties declared has accounted for 1 / 4, almost all of which are called "XXX tinib" There is no clinically differentiated me too product, which will be eliminated soon even if it goes on the market The lack of innovation ability at the source has nothing to do with the lack of clinical participation On the one hand, the research and development of new drugs can not effectively meet the clinical needs, most of which are on the way, can not be widely used in clinical practice, and can not stimulate the research and development momentum; on the other hand, the clinical needs should always be filled, so the imported drugs are still the "trump card", and the domestic drugs are always the follow-up generic drugs, unable to form a differentiated competitive strength Looking at the world, the FDA has always been "meeting clinical needs" oriented, throughout its new drug review philosophy, that is: compared with the existing drugs, the drugs that can significantly benefit patients and have clinical advantages can be approved for listing, and realize the positive interaction between clinical and research Of course, getting through the obstruction of clinical research and development is not to let doctors do research and development, but to help accurately calibrate the direction Let the innovation force flow fully, let the drug pricing power of the big country not fall aside, and reduce the drug burden of the common people will be better implemented.